Role of sorafenib in renal cell carcinoma: Focus on elderly patients

Expert Review of Anticancer Therapy

Volumn 11, Issue 11, 2011, Pages 1689-1692

  Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Elderly; Renal cell cancer; Sorafenib; Targeted therapies

Indexed keywords

PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ARTICLE; ASTHENIA; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COMORBIDITY; COUGHING; DIARRHEA; DRUG EFFICACY; FATIGUE; GERIATRIC CARE; HEALTH STATUS; HUMAN; KIDNEY METASTASIS; OVERALL SURVIVAL; PHYSICIAN; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RENAL CELL CARCINOMA; SELF REPORT; SURVIVAL RATE; TREATMENT OUTCOME; AGE; AGED; DISEASE FREE SURVIVAL; KIDNEY CARCINOMA; KIDNEY TUMOR;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84858717040     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.153     Document Type: Article

References (21)

1. Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. DOI: 10.1111/j.1464–410X.2010.09829.x (2010) Epub ahead of print
2. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36, 16–23 (2010).
3. Zustovich F, Lombardi G, Pastorelli D et al. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. OA J. Urol. 3, 1–14 (2011).
4. Escudier B, Eisen T, Stadler WM et al.; TARGET study group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cellcarcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312–3318 (2009).
6. Rini BI, Szczylik C, Tannir NM et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, doubleblind, placebo-controlled, Phase II study J. Clin. Oncol. 29(Suppl. 7) (2011) (Abstract 309).
7. Procopio G, Verzoni E, Bracarda S et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br. J. Cancer 104, 1256–1261 (2011).
8. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116, 1272–1280 (2010).
9. Pascual D, Borque A. Epidemiology of kidney cancer. Adv. Urol. 2008, 782381 (2008).
10. Bellmunt J, Calvo E, Castellano D et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother. Pharmacol. 63(Suppl. 1), S1–S13 (2009).
11. Eisen T, Oudard S, Szczylik C et al.; TARGET study group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer. Inst. 100, 1454–1463 (2008).
12. Bukowski RM, Stadler WM, McDermott DF et al. Safety and efficacy of sorafenib in elderly patients treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology 78, 340–347 (2010).
13. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EUARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol. 22, 1812–1823 (2011).
14. Bukowski RM. Safety and efficacy of sorafenib in elderly patients (pts) >65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J. Clin. Oncol. 26 (2008) (Abstract 5045).
15. Townsley CA, Pond GR, Oza AM et al. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin. Cancer Res. 12(7 Pt 1), 2141–2149 (2006).
16. Procopio G, Bellmunt J, Dutcher JP et al. Sorafenib in older patients with advanced renal cell carcinoma: subanalysis by age of an integrated database of 8 companysponsored clinical trials. Ann. Oncol. 21(Suppl. 8) (2010) (Poster 906P).
17. Fratino L, Bearz A, Polesel J, Lestuzzi C, Vaccher E, Tirelli U. Use of a comprehensive geriatric assessment (CGA) to guide the use of sorafenib in unfit elderly patients (EP) with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. 28(Suppl.) (2010) (Abstract e19636).
18. Hutson TE, Bukowski RM, Rini BI et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 4604).
19. Bajetta E, Ravaud A, Bracarda S et al. A randomized Phase III study of firstline bevacizumab (BEV) plus interferona 2a (IFN) versus IFN alone in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5095).
20. Hutson TE, Calvo E, Escudier BJ et al. Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study. Presented at: ASCO 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010 (Abstract 362).
21. Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).